JAMP COLESEVELAM DIN 02566869
Health Canada record
| Active ingredient(s) | COLESEVELAM HYDROCHLORIDE 625 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C10AC04 COLESEVELAM |
| Original market date | |
| Current status date | 20-Mar-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing COLESEVELAM HYDROCHLORIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02494051 | APO-COLESEVELAM | APOTEX INC | Tablet | COLESEVELAM HYDROCHLORIDE 625 MG | Marketed |
| 02373955 | LODALIS | BAUSCH HEALTH, CANADA INC. | Tablet | COLESEVELAM HYDROCHLORIDE 625 MG | Marketed |
| 02432463 | LODALIS | BAUSCH HEALTH, CANADA INC. | Powder For Suspension | COLESEVELAM HYDROCHLORIDE 3.75 G | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37147 | 2026-03-20 | Abbreviated New Drug Submission (ANDS) |
International API supply for COLESEVELAM HYDROCHLORIDE
8 active FDA Drug Master Files.
Request a quote for JAMP COLESEVELAM